drugset
Drugs / Norovirus Bivalent (GI.1 / GII.4) Vaccine
last change Mar 2024 re-read 3 minutes ago

Norovirus Bivalent (GI.1 / GII.4) Vaccine

Vaccine

Developed for
gastroenteritis · norovirus infectious disease
Investigated by
Beijing Zhong Sheng Heng Yi Pharmaceutical Technology Co., Ltd. · Lanzhou Institute of Biological Products Co., Ltd · National Vaccine and Serum Institute, China · Zhengzhou University

Trials 1

today NCT04941261 · Ph 2
20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT04941261 Jun 2021 → Feb 2024 gastroenteritis, norovirus infectious disease National Vaccine and Serum Institute, China Unknown No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Norovirus Bivalent (GI.1 / GII.4) Vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT04941261 ↗
Modality Vaccine “Norovirus Bivalent (GI.1 / GII.4) Vaccine” NCT04941261 ↗
Route Intramuscular “Intramuscular injection of middle-dose Norovirus Bivalent (GI.1 / GII.4) Vaccine in the deltoid muscle of the upper arm” NCT04941261 ↗